Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial of AZD6738 Alone and in Combination With Olaparib in Patients With Selected Solid Tumor Malignancies

Next Previous
Trial Profile

Phase II Trial of AZD6738 Alone and in Combination With Olaparib in Patients With Selected Solid Tumor Malignancies

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2019

At a glance

  • Drugs AZD 6738 (Primary) ; Olaparib (Primary)
  • Indications Adenocarcinoma; Carcinoma; Pancreatic cancer; Renal cell carcinoma; Solid tumours; Urogenital cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 21 Dec 2018 Status changed from not yet recruiting to recruiting.
    • 19 Oct 2018 Planned initiation date changed from 1 Oct 2018 to 1 Dec 2018.
    • 28 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top